ARTICLE | Clinical News
ZT-031: SPA received
July 28, 2008 7:00 AM UTC
Zelos received an SPA from FDA for a 24-month Phase III trial in 3,255 postmenopausal women to compare subcutaneous ZT-031 against Fosamax alendronate from Merck & Co. Inc. (NYSE:MRK, Whitehouse Sta...